［38］Zava T T，Zava D T．Assessment of Japanese iodine intake based on seaweed consumption in Japan：A literature-based analysis［J］．Thyroid Res，2011，4：14.
［30］Chung C S，et al．Incidence of second malignancies among patients treated with proton versus photon radiation［J］．Int J Radiat Oncol Biol Phys，2013，87（1）：46-52.
［3］Yock T I，et al．Quality of life outcomes in proton and photon treated pediatric brain tumor survivors［J］．Radiother Oncol，2014，113（1）：89-94.
［42］Pederson T，Mukherjee S．The Emperor of All Maladies A Biography of Cancer［J］．Science，2011，332（6028）：423-423.
［5］Warren G W，et al．The 2014 Surgeon General's report：“The health consequences of smoking — 50 years of progress”：a paradigm shift in cancer care［J］．Cancer，2014，120（13）：1914-1916.
［49］Lawenda B D，et al．Should supplemental antioxidant administration be avoided during chemotherapy and radiation therapy？［J］．J Natl Cancer Inst，2008，100（11）：773-783.
［77］CBSnews .Killing Cancer［OL］．http://www.cbsnews.com/news/polio-cancer-treatment-duke-university-60-minutes-scott-pelley/2015，3.29.
［32］Wang Y C，et al．Comparison of Cancer Incidence between China and the USA［J］．Cancer Biol Med，2012，9（2）：128-132.
［17］Gubin M M，et al．Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens［J］．Nature，2014，515（7528）：577-581.
［50］Dishop M K，Kuruvilla S．Primary and metastatic lung tumors in the pediatric population：a review and 25-year experience at a large children's hospital［J］．Arch Pathol Lab Med，2008，132（7）：1079-1103.
［58］Murgia C，et al．Clonal origin and evolution of a transmissible cancer［J］．Cell，2006，126（3）：477-487.
［79］Li Z，et.al，Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells［J］．Cancer Cell．2009，2；15（6）：501-513.
［8］Shi Y，et al．A prospective，molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology （PIONEER） ［J］．J Thorac Oncol，2014，9（2）：154-162.
［64］Srivastava S R．Gopal-Srivastava，Biomarkers in cancer screening：a public health perspective［J］．J Nutr，2002，132（8 Suppl）：2471S-2475S.
［34］Seralini G E，et al．Long term toxicity of a Roundup herbicide and a Roundup-tolerant genetically modified maize［J］．Food Chem Toxicol，2012，50（11）：4221-4231.
［76］Southam C M，Moore A E．Clinical studies of viruses as antineoplastic agents with particular reference to Egypt 101 virus［J］．Cancer，1952，5（5）：1025-1034.
［70］Newcomb P A，Carbone P P．The health consequences of smoking．Cance［J］r．Med Clin North Am，1992，76（2）：305-331.
［22］Wolchok J D，et al．Nivolumab plus ipilimumab in advanced melanoma［J］．N Engl J Med，2013，369（2）：122-133.
［24］Vacchelli E，et al．Trial watch：Oncolytic viruses for cancer therapy［J］．Oncoimmunology，2013，2（6）：e24612.
［25］Shi Y，et al．Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer （ICOGEN）：a randomised，double-blind phase 3 non-inferiority trial［J］．Lancet Oncol，2013，14（10）：953-961.
［51］Ballen K K，et al．Collection and preservation of cord blood for personal use［J］．Biol Blood Marrow Transplant，2008，14（3）：356-363.
［72］Rosenberg S A，et al．Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer［J］．N Engl J Med，1985，313（23）：1485-1492.
［21］Retraction notice to“Long term toxicity of a Roundup herbicide and a Roundup-tolerant genetically modified maize”Food Chem Toxicol，2014，63：244.
［37］An S J，et al．Identification of enriched driver gene alterations in subgroups of non-small cell lung cancer patients based on histology and smoking status［J］．PLoS One，2012，7（6）：e40109.
［9］Shen L，Ji H F．Ceritinib in ALK-rearranged non-small-cell lung cancer［J］．N Engl J Med，2014，370（26）：2537.
［10］Shaw A T，Engelman J A．Ceritinib in ALK-rearranged non-small-cell lung cancer［J］．N Engl J Med，2014，370（26）：2537-2539.
［63］van der Zee，J．Heating the patient：a promising approach？［J］．Ann Oncol，2002，13（8）：1173-1184.
［23］Watson I R，et al．Emerging patterns of somatic mutations in cancer［J］．Nat Rev Genet，2013，14（10）：703-718.
［54］Kelly E，Russell S J．History of oncolytic viruses：genesis to genetic engineering［J］．Mol Ther，2007，15（4）：651-659.
［48］Little M P．Cancer and non-cancer effects in Japanese atomic bomb survivors［J］．J Radiol Prot，2009，29（2A）：A43-59.
［7］Snyder A，et al．Genetic basis for clinical response to CTLA-4 blockade in melanoma［J］．N Engl J Med，2014，371（23）：2189-2199.
［20］Bonadies D C，et al．Adverse events in cancer genetic testing：the third case series［J］．Cancer J，2014，20（4）：246-53.
［67］Patterson R E，et al．Vitamin supplements and cancer risk：the epidemiologic evidence［J］．Cancer Causes Control，1997，8（5）：786-802.
［78］https://clinicaltrials.gov/ct2/show/NCT0149189
［47］Sawka A M，et al．Second primary malignancy risk after radioactive iodine treatment for thyroid cancer：a systematic review and meta-analysis［J］．Thyroid，2009，19（5）：451-457.
［52］Schoder H，Gonen M．Screening for cancer with PET and PET/CT：potential and limitations［J］．J Nucl Med，2007，48 Suppl 1：4S-18S.
［62］Ludwig J A，Weinstein J N．Biomarkers in cancer staging，prognosis and treatment selection［J］．Nat Rev Cancer，2005，5（11）：845-856.
［41］Ramaekers B L，et al．Systematic review and meta-analysis of radiotherapy in various head and neck cancers：comparing photons，carbon-ions and protons［J］．Cancer Treat Rev，2011，37（3）：185-201.
［69］Ferrara J L，Abhyankar S，Gilliland D G.Cytokine storm of graft-versus-host disease：a critical effector role for interleukin-1［J］．Transplant Proc，1993，25（1 Pt 2）：1216-1217.
［2］Zhou C．Lung cancer molecular epidemiology in China：recent trends［J］．Transl Lung Cancer Res．2014，3（5）：270-279.
［53］McLaughlin J R，et al．Reproductive risk factors for ovarian cancer in carriers of BRCA1 or BRCA2 mutations：a case-control study［J］．Lancet Oncol，2007，8（1）：26-34.
［6］Solomon B J，et al．First-line crizotinib versus chemotherapy in ALK-positive lung cancer［J］．N Engl J Med，2014，371（23）：2167-2177.
［71］Martuza R L，et al．Experimental therapy of human glioma by means of a genetically engineered virus mutant［J］．Science，1991，252（5007）：854-856.
［73］Morahan P S，et al．Paradoxical effects of immunopotentiators on tumors and tumor viruses［J］．J Infect Dis，1976，133 Suppl：A249-255.
［46］Domchek S M，et al．Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality［J］．JAMA，2010，304（9）：967-975.
［27］Li Y，et al．Clinical significance of EML4-ALK fusion gene and association with EGFR and KRAS gene mutations in 208 Chinese patients with non-small cell lung cancer［J］．PLoS One，2013，8（1）：e52093.
［31］Arcila M E，et al．EGFR exon 20 insertion mutations in lung adenocarcinomas：prevalence，molecular heterogeneity，and clinicopathologic characteristics［J］．Mol Cancer Ther，2013，12（2）：220-229.
［44］Miller L H，Su X．Artemisinin：discovery from the Chinese herbal garden［J］．Cell，2011，146（6）：855-858.
［39］Wagle N，et al．Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling［J］．J Clin Oncol，2011，29（22）：3085-3096.
［75］Moore A E．Effects of viruses on tumors［J］．Annu Rev Microbiol，1954，8：393-410.
［56］Bjelakovic G，et al．Mortality in randomized trials of antioxidant supplements for primary and secondary prevention：systematic review and meta-analysis［J］．JAMA，2007，297（8）：842-857.
［59］Garber K．China approves world's first oncolytic virus therapy for cancer treatment［J］．J Natl Cancer Inst，2006，98（5）：298-300.
［15］Lin Y，et al．Identification and characterization of alphavirus M1 as a selective oncolytic virus targeting ZAP-defective human cancers［J］．Proc Natl Acad Sci U S A，2014，111（42）：E4504-4512.
［26］Nixon I J，et al．The results of selective use of radioactive iodine on survival and on recurrence in the management of papillary thyroid cancer，based on Memorial Sloan-Kettering Cancer Center risk group stratification［J］．Thyroid，2013，23（6）：683-694.
［19］Brastianos K，et al．Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas［J］．Nat Genet，2014，46（2）：161-165.
［60］Druker B J，et al．Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia［J］．N Engl J Med，2006，355（23）：2408-2417.
［45］Kantoff W，et al．Sipuleucel-T immunotherapy for castration-resistant prostate cancer［J］．N Engl J Med，2010，363（5）：411-422.
［57］Pearse A M，Swift K．Allograft theory：transmission of devil facial-tumour disease［J］．Nature，2006，439（7076）：549.
［4］Yadav M，et al．Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing［J］．Nature，2014，515（7528）：572-576.
［36］Govindan R，et al．Genomic landscape of non-small cell lung cancer in smokers and never-smokers［J］．Cell，2012，150（6）：1121-1134.
［18］Gragert L，et al．HLA match likelihoods for hematopoietic stem-cell grafts in the U．S．registry［J］．N Engl J Med，2014，371（4）：339-348.
［29］Hamid O，et al．Safety and tumor responses with lambrolizumab （anti-PD-1） in melanoma［J］．N Engl J Med，2013，369（2）：134-144.
［80］Gromeier M．et.al，Oncolytic polio virotherapy of cancer.Cancer［J］．2014，120（21）：3277-3286.
［43］Moeller B J，et al．Low early ototoxicity rates for pediatric medulloblastoma patients treated with proton radiotherapy［J］．Radiat Oncol，2011，6：58.
［55］Eapen M，et al．Outcomes of transplantation of unrelated donor umbilical cord blood and bone marrow in children with acute leukaemia：a comparison study［J］．Lancet，2007，369（9577）：1947-1954.
［28］Lawrence M S，et al．Mutational heterogeneity in cancer and the search for new cancer-associated genes［J］．Nature，2013，499（7457）：214-218.
［74］Yohn D S，et al.Oncolytic potentials of nonhuman viruses for human cancer．Ⅱ．Effects of five viruses on heterotransplantable human tumors［J］．J Natl Cancer Inst，1968，41（2）：523-529.
［33］Topalian S L，et al．Safety，activity，and immune correlates of anti-PD-1 antibody in cancer［J］．N Engl J Med，2012，366（26）：2443-2454.
［1］Metzger M J，et al．Horizontal transmission of clonal cancer cells causes leukemia in soft-shell clams［J］．Cell，2015，161（2）：255-263.
［12］Mitin T A，Zietman L．Promise and pitfalls of heavy-particle therapy［J］．J Clin Oncol，2014，32（26）：2855-2863.
［68］Jha P，et al．The antioxidant vitamins and cardiovascular disease．A critical review of epidemiologic and clinical trial data［J］．Ann Intern Med，1995，123（11）：860-872.
［61］Lundkvist J，et al．Cost-effectiveness of proton radiation in the treatment of childhood medulloblastoma［J］．Cancer，2005，103（4）：793-801.
［14］Maude S L，et al．Chimeric antigen receptor T cells for sustained remissions in leukemia［J］．N Engl J Med，2014，371（16）：1507-1517.
［13］Mendenhall N P，et al．Five-year outcomes from 3 prospective trials of image-guided proton therapy for prostate cancer［J］．Int J Radiat Oncol Biol Phys，2014，88（3）：596-602.
［66］Nishimura H，et al．Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor［J］．Immunity，1999，11（2）：141-151.
［40］Sequist L V，et al．Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors［J］．Sci Transl Med，2011，3（75）：75ra26.
［65］Miralbell R，et al．Potential reduction of the incidence of radiation-induced second cancers by using proton beams in the treatment of pediatric tumors［J］．Int J Radiat Oncol Biol Phys，2002，54（3）：824-829.
［35］Lim S S，et al．A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions，1990-2010：a systematic analysis for the Global Burden of Disease Study 2010［J］．Lancet，2012，380（9859）：2224-2260.
［11］Sayin V I，et al．Antioxidants accelerate lung cancer progression in mice［J］．Sci Transl Med，2014，6（221）：221ra15.
［16］Herbst R S，et al．Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients［J］．Nature，2014，515（7528）：563-567.
